Latest deal gives Almirall access to Wuxi Biologics' antibody platforms

9 January 2020

Ambitious dermatology specialist Almirall (ALM: MC) has announced a deal with China-based WuXi Biologics (HKG: 2269).

The Spanish drugmaker wants to be a global leader in medical dermatology and is embarking on a series of collaborations to help achieve this, including entering into an option agreement to buy Bioniz Therapeutics, a deal that was announced on Wednesday.

"This agreement is a big step forward for us in our objective in becoming a leader in biologic medical dermatology"On Thursday, the Barcelona-based company unveiled a further agreement, this time giving it access to WuXi Biologics’ proprietary antibody platforms, including WuXiBody, to discover multiple new bispecific antibodies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK